LARIAM mefloquine 250mg tablets

Страна: Австралия

Език: английски

Източник: Department of Health (Therapeutic Goods Administration)

Активна съставка:

mefloquine hydrochloride, Quantity: 274.09 mg (Equivalent: mefloquine, Qty 250 mg)

Предлага се от:

Pharmaco Australia Ltd

Лекарствена форма:

Tablet, uncoated

Композиция:

Excipient Ingredients: ammonium alginate; crospovidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified talc; maize starch; poloxamer

Начин на приложение:

Oral

Броя в опаковка:

8 tablets

Вид предписание :

(S4) Prescription Only Medicine

Терапевтични показания:

Malaria treatment: LARIAM is indicated for the treatment of acute attacks of malaria due to P.falciparum infection resistant to conventional antimalarial drugs. Following therapy of mixed P.falciparum/P.vivax malaria with LARIAM relapse prophylaxis with an 8-aminoquinoline derivative (e.g. primaquine) should be considered in order to eliminate liver forms of P.vivax. Malaria Prophylaxis: For travellers to countries with documented chloroquine and antifolate combination ( [sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant P.falciparum malaria, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas (between the dusk to dawn period). For travellers hypersensitive to sulphonamides and sulphones, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas, (between the dusk to dawn period) in countries with high level chloroquine-resistant P.fal

Каталог на резюме:

Visual Identification: Cylindrical biplanar, white to off-white tablet, cross-scored break bars on both faces, marked "LA", "RI", "AM" & "CP" in each quadrant on one face.; Container Type: Blister Pack; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

Статус Оторизация:

Registered

Дата Оторизация:

1993-01-27

Листовка

LARIAM – Consumer Medicine Information 2019-11 v1.0
1
LARIAM
®
_contains the active ingredient mefloquine _
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Lariam tablets.
It does not contain all the available
information.
It does not take the place of talking to
your doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Lariam tablets
against the benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT LARIAM IS USED
FOR
Lariam is used to prevent and treat
malaria.
Lariam contains the active ingredient
mefloquine. Lariam belongs to a
group of medicines called quinolones
(pronounced kwin-o-lones).
Lariam works by killing the parasites
that may cause or have caused
malaria.
_WHERE AND HOW YOU CAN _
_CONTRACT MALARIA _
Malaria is an infectious disease that
is widespread in tropical and
subtropical areas of Africa, Latin
America, Asia and countries around
the Pacific. There are different forms
of malaria, each of them caused by a
specific parasite transmitted to
humans by the bite of the Anopheles
mosquito.
_PRECAUTIONS AGAINST MALARIA _
The best protection against malaria is
to avoid mosquito bites. The
mosquito that causes malaria mainly
bites between dusk and dawn.
Therefore the following
precautionary measures are
recommended:
•
during this period, wear light-
coloured clothing that covers as
much of your skin as possible
•
apply mosquito repellent to your
uncovered skin and to your
clothes
•
when sleeping in rooms that are
not protected against mosquitoes,
use an effective mosquito net well
tucked under the mattress
•
additional protection is provided
by smoke spirals, insect sprays
and candles.
_SYMPTOMS OF MALARIA _
The symptoms of malaria may often
be mild. However, malaria should be
suspected if, after one week in a
malarial area, you suffer unexplained
fever with

Данни за продукта

2019-11 v1.0
1
AUSTRALIAN PRODUCT INFORMATION – LARIAM (MEFLOQUINE
HYDROCHLORIDE) TABLETS
1
NAME OF THE MEDICINE
Mefloquine hydrochloride
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lariam tablets contain 250 mg mefloquine in the form of mefloquine
hydrochloride (274.09 mg).
Lariam (mefloquine) is an antimalarial belonging to the quinoline
methanol group of medicines and is
structurally related to quinine.
Excipients with known effect:
Lactose monohydrate
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Tablets.
Lariam tablets are cylindrical biplanar, white to off-white,
cross-scored with break bars on both faces
and marked with "LA", "RI", "AM" and “CP” in each quadrant of one
face.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
MALARIA TREATMENT
Lariam is indicated for the treatment of acute attacks of malaria due
to
_P. falciparum_
infection
resistant to conventional antimalarial drugs.
Following therapy of mixed
_P. falciparum_
and
_P. vivax_
malaria with Lariam, relapse
chemoprophylaxis with an 8-aminoquinoline derivative (e.g. primaquine)
should be considered in
order to eliminate hepatic forms of
_P. vivax_
.
MALARIA CHEMOPROPHYLAXIS
For travellers to countries with documented chloroquine and antifolate
combination
([sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant
_P. falciparum_
malaria, who are
considered to be at high risk for malaria in view of their residence
or travel (of up to 3 months
duration) through rural areas (between the dusk to dawn period).
For travellers hypersensitive to sulphonamides and sulphones, who are
considered to be at high risk
for malaria in view of their residence or travel (of up to 3 months
duration) through rural areas,
(between the dusk to dawn period) in countries with high level
chloroquine-resistant
_P. falciparum_
malaria.
2019-11 v1.0
2
4.2
D
OSE AND METHOD OF ADMINISTRATION
_MALARIA TREATMENT _
ADULTS AND CHILDREN OF MORE THAN 45 KG BODYWEIGHT:
The recommended total dosage of Lariam, 1,250 mg accord